nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A4—Thiotepa—urinary bladder cancer	0.0617	0.231	CbGbCtD
Aprepitant—CYP3A5—Etoposide—urinary bladder cancer	0.0429	0.161	CbGbCtD
Aprepitant—CYP1A2—Fluorouracil—urinary bladder cancer	0.0383	0.143	CbGbCtD
Aprepitant—CYP2C9—Fluorouracil—urinary bladder cancer	0.0345	0.129	CbGbCtD
Aprepitant—CYP1A2—Etoposide—urinary bladder cancer	0.0319	0.12	CbGbCtD
Aprepitant—CYP2C9—Cisplatin—urinary bladder cancer	0.0293	0.11	CbGbCtD
Aprepitant—TACR3—smooth muscle tissue—urinary bladder cancer	0.0171	0.161	CbGeAlD
Aprepitant—CYP3A4—Etoposide—urinary bladder cancer	0.0167	0.0627	CbGbCtD
Aprepitant—TACR3—female reproductive system—urinary bladder cancer	0.0132	0.124	CbGeAlD
Aprepitant—CYP3A4—Doxorubicin—urinary bladder cancer	0.0114	0.0428	CbGbCtD
Aprepitant—CYP2C19—urine—urinary bladder cancer	0.00994	0.0936	CbGeAlD
Aprepitant—TACR1—prostate gland—urinary bladder cancer	0.00934	0.0879	CbGeAlD
Aprepitant—CYP1A2—urine—urinary bladder cancer	0.00812	0.0764	CbGeAlD
Aprepitant—CYP2C9—urine—urinary bladder cancer	0.0077	0.0725	CbGeAlD
Aprepitant—TACR1—smooth muscle tissue—urinary bladder cancer	0.00661	0.0623	CbGeAlD
Aprepitant—TACR1—renal system—urinary bladder cancer	0.00637	0.0599	CbGeAlD
Aprepitant—CYP3A4—urine—urinary bladder cancer	0.00587	0.0553	CbGeAlD
Aprepitant—TACR1—female reproductive system—urinary bladder cancer	0.0051	0.048	CbGeAlD
Aprepitant—TACR1—lymph node—urinary bladder cancer	0.00298	0.0281	CbGeAlD
Aprepitant—CYP3A5—prostate gland—urinary bladder cancer	0.00281	0.0265	CbGeAlD
Aprepitant—CYP1A2—renal system—urinary bladder cancer	0.00199	0.0187	CbGeAlD
Aprepitant—CYP3A5—renal system—urinary bladder cancer	0.00192	0.018	CbGeAlD
Aprepitant—CYP2C19—vagina—urinary bladder cancer	0.00176	0.0166	CbGeAlD
Aprepitant—CYP2C9—female reproductive system—urinary bladder cancer	0.00151	0.0142	CbGeAlD
Aprepitant—CYP3A4—renal system—urinary bladder cancer	0.00144	0.0135	CbGeAlD
Aprepitant—CYP3A5—vagina—urinary bladder cancer	0.00139	0.0131	CbGeAlD
Aprepitant—CYP3A4—female reproductive system—urinary bladder cancer	0.00115	0.0108	CbGeAlD
Aprepitant—Bradycardia—Epirubicin—urinary bladder cancer	0.000283	0.000577	CcSEcCtD
Aprepitant—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000282	0.000576	CcSEcCtD
Aprepitant—Renal failure—Doxorubicin—urinary bladder cancer	0.000281	0.000574	CcSEcCtD
Aprepitant—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000281	0.000573	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000281	0.000573	CcSEcCtD
Aprepitant—Urticaria—Etoposide—urinary bladder cancer	0.00028	0.000571	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—urinary bladder cancer	0.000279	0.000569	CcSEcCtD
Aprepitant—Abdominal pain—Etoposide—urinary bladder cancer	0.000278	0.000568	CcSEcCtD
Aprepitant—Body temperature increased—Etoposide—urinary bladder cancer	0.000278	0.000568	CcSEcCtD
Aprepitant—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000278	0.000568	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000278	0.000568	CcSEcCtD
Aprepitant—Eye disorder—Methotrexate—urinary bladder cancer	0.000277	0.000566	CcSEcCtD
Aprepitant—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000277	0.000566	CcSEcCtD
Aprepitant—Tinnitus—Methotrexate—urinary bladder cancer	0.000277	0.000565	CcSEcCtD
Aprepitant—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000276	0.000564	CcSEcCtD
Aprepitant—Asthenia—Cisplatin—urinary bladder cancer	0.000276	0.000563	CcSEcCtD
Aprepitant—Pharyngitis—Epirubicin—urinary bladder cancer	0.000276	0.000563	CcSEcCtD
Aprepitant—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000275	0.000562	CcSEcCtD
Aprepitant—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000274	0.00056	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—urinary bladder cancer	0.000273	0.000557	CcSEcCtD
Aprepitant—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000273	0.000557	CcSEcCtD
Aprepitant—Urethral disorder—Epirubicin—urinary bladder cancer	0.000272	0.000556	CcSEcCtD
Aprepitant—Angiopathy—Methotrexate—urinary bladder cancer	0.000269	0.000549	CcSEcCtD
Aprepitant—Immune system disorder—Methotrexate—urinary bladder cancer	0.000268	0.000547	CcSEcCtD
Aprepitant—Dizziness—Fluorouracil—urinary bladder cancer	0.000268	0.000547	CcSEcCtD
Aprepitant—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000267	0.000546	CcSEcCtD
Aprepitant—Chills—Methotrexate—urinary bladder cancer	0.000266	0.000543	CcSEcCtD
Aprepitant—Diarrhoea—Cisplatin—urinary bladder cancer	0.000263	0.000537	CcSEcCtD
Aprepitant—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000263	0.000536	CcSEcCtD
Aprepitant—Alopecia—Methotrexate—urinary bladder cancer	0.000262	0.000535	CcSEcCtD
Aprepitant—Vomiting—Gemcitabine—urinary bladder cancer	0.000262	0.000535	CcSEcCtD
Aprepitant—Bradycardia—Doxorubicin—urinary bladder cancer	0.000262	0.000534	CcSEcCtD
Aprepitant—Mental disorder—Methotrexate—urinary bladder cancer	0.00026	0.000531	CcSEcCtD
Aprepitant—Rash—Gemcitabine—urinary bladder cancer	0.00026	0.00053	CcSEcCtD
Aprepitant—Dermatitis—Gemcitabine—urinary bladder cancer	0.00026	0.00053	CcSEcCtD
Aprepitant—Eye disorder—Epirubicin—urinary bladder cancer	0.000259	0.00053	CcSEcCtD
Aprepitant—Hypersensitivity—Etoposide—urinary bladder cancer	0.000259	0.000529	CcSEcCtD
Aprepitant—Tinnitus—Epirubicin—urinary bladder cancer	0.000259	0.000528	CcSEcCtD
Aprepitant—Malnutrition—Methotrexate—urinary bladder cancer	0.000258	0.000527	CcSEcCtD
Aprepitant—Erythema—Methotrexate—urinary bladder cancer	0.000258	0.000527	CcSEcCtD
Aprepitant—Headache—Gemcitabine—urinary bladder cancer	0.000258	0.000527	CcSEcCtD
Aprepitant—Flushing—Epirubicin—urinary bladder cancer	0.000258	0.000526	CcSEcCtD
Aprepitant—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000258	0.000526	CcSEcCtD
Aprepitant—Vomiting—Fluorouracil—urinary bladder cancer	0.000258	0.000526	CcSEcCtD
Aprepitant—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000256	0.000522	CcSEcCtD
Aprepitant—Rash—Fluorouracil—urinary bladder cancer	0.000255	0.000522	CcSEcCtD
Aprepitant—Dermatitis—Fluorouracil—urinary bladder cancer	0.000255	0.000521	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000255	0.00052	CcSEcCtD
Aprepitant—Headache—Fluorouracil—urinary bladder cancer	0.000254	0.000518	CcSEcCtD
Aprepitant—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000254	0.000518	CcSEcCtD
Aprepitant—Dysgeusia—Methotrexate—urinary bladder cancer	0.000253	0.000516	CcSEcCtD
Aprepitant—Asthenia—Etoposide—urinary bladder cancer	0.000252	0.000515	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000252	0.000515	CcSEcCtD
Aprepitant—Angiopathy—Epirubicin—urinary bladder cancer	0.000252	0.000514	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000252	0.000514	CcSEcCtD
Aprepitant—Immune system disorder—Epirubicin—urinary bladder cancer	0.000251	0.000512	CcSEcCtD
Aprepitant—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00025	0.000511	CcSEcCtD
Aprepitant—Back pain—Methotrexate—urinary bladder cancer	0.00025	0.00051	CcSEcCtD
Aprepitant—Chills—Epirubicin—urinary bladder cancer	0.000249	0.000509	CcSEcCtD
Aprepitant—Pruritus—Etoposide—urinary bladder cancer	0.000249	0.000508	CcSEcCtD
Aprepitant—Alopecia—Epirubicin—urinary bladder cancer	0.000245	0.000501	CcSEcCtD
Aprepitant—Nausea—Gemcitabine—urinary bladder cancer	0.000245	0.0005	CcSEcCtD
Aprepitant—Vomiting—Cisplatin—urinary bladder cancer	0.000244	0.000499	CcSEcCtD
Aprepitant—Mental disorder—Epirubicin—urinary bladder cancer	0.000243	0.000497	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000243	0.000496	CcSEcCtD
Aprepitant—Rash—Cisplatin—urinary bladder cancer	0.000242	0.000494	CcSEcCtD
Aprepitant—Dermatitis—Cisplatin—urinary bladder cancer	0.000242	0.000494	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—urinary bladder cancer	0.000242	0.000493	CcSEcCtD
Aprepitant—Erythema—Epirubicin—urinary bladder cancer	0.000242	0.000493	CcSEcCtD
Aprepitant—Diarrhoea—Etoposide—urinary bladder cancer	0.000241	0.000492	CcSEcCtD
Aprepitant—Nausea—Fluorouracil—urinary bladder cancer	0.000241	0.000491	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—urinary bladder cancer	0.00024	0.00049	CcSEcCtD
Aprepitant—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00024	0.000489	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—urinary bladder cancer	0.00024	0.000489	CcSEcCtD
Aprepitant—Anaemia—Methotrexate—urinary bladder cancer	0.000239	0.000487	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—urinary bladder cancer	0.000238	0.000487	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000238	0.000487	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—urinary bladder cancer	0.000238	0.000486	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—urinary bladder cancer	0.000237	0.000483	CcSEcCtD
Aprepitant—Back pain—Epirubicin—urinary bladder cancer	0.000234	0.000477	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—urinary bladder cancer	0.000233	0.000476	CcSEcCtD
Aprepitant—Malaise—Methotrexate—urinary bladder cancer	0.000233	0.000475	CcSEcCtD
Aprepitant—Dizziness—Etoposide—urinary bladder cancer	0.000233	0.000475	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—urinary bladder cancer	0.000232	0.000474	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000232	0.000474	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000232	0.000473	CcSEcCtD
Aprepitant—Chills—Doxorubicin—urinary bladder cancer	0.000231	0.000471	CcSEcCtD
Aprepitant—Nausea—Cisplatin—urinary bladder cancer	0.000228	0.000466	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—urinary bladder cancer	0.000227	0.000463	CcSEcCtD
Aprepitant—Cough—Methotrexate—urinary bladder cancer	0.000225	0.00046	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—urinary bladder cancer	0.000225	0.000459	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000224	0.000458	CcSEcCtD
Aprepitant—Convulsion—Methotrexate—urinary bladder cancer	0.000224	0.000457	CcSEcCtD
Aprepitant—Vomiting—Etoposide—urinary bladder cancer	0.000224	0.000457	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—urinary bladder cancer	0.000224	0.000457	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—urinary bladder cancer	0.000224	0.000457	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—urinary bladder cancer	0.000223	0.000456	CcSEcCtD
Aprepitant—Rash—Etoposide—urinary bladder cancer	0.000222	0.000453	CcSEcCtD
Aprepitant—Dermatitis—Etoposide—urinary bladder cancer	0.000222	0.000453	CcSEcCtD
Aprepitant—Headache—Etoposide—urinary bladder cancer	0.00022	0.00045	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—urinary bladder cancer	0.00022	0.00045	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—urinary bladder cancer	0.00022	0.000449	CcSEcCtD
Aprepitant—Chest pain—Methotrexate—urinary bladder cancer	0.00022	0.000449	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—urinary bladder cancer	0.00022	0.000449	CcSEcCtD
Aprepitant—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000219	0.000447	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000218	0.000446	CcSEcCtD
Aprepitant—Malaise—Epirubicin—urinary bladder cancer	0.000218	0.000445	CcSEcCtD
Aprepitant—Discomfort—Methotrexate—urinary bladder cancer	0.000217	0.000443	CcSEcCtD
Aprepitant—Syncope—Epirubicin—urinary bladder cancer	0.000217	0.000442	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—urinary bladder cancer	0.000216	0.000442	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000215	0.000439	CcSEcCtD
Aprepitant—Palpitations—Epirubicin—urinary bladder cancer	0.000214	0.000436	CcSEcCtD
Aprepitant—Confusional state—Methotrexate—urinary bladder cancer	0.000213	0.000434	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000212	0.000434	CcSEcCtD
Aprepitant—Cough—Epirubicin—urinary bladder cancer	0.000211	0.000431	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000211	0.00043	CcSEcCtD
Aprepitant—Convulsion—Epirubicin—urinary bladder cancer	0.000209	0.000427	CcSEcCtD
Aprepitant—Infection—Methotrexate—urinary bladder cancer	0.000209	0.000427	CcSEcCtD
Aprepitant—Nausea—Etoposide—urinary bladder cancer	0.000209	0.000427	CcSEcCtD
Aprepitant—Hypertension—Epirubicin—urinary bladder cancer	0.000209	0.000426	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000208	0.000424	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000207	0.000422	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—urinary bladder cancer	0.000207	0.000422	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000206	0.000421	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—urinary bladder cancer	0.000206	0.00042	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—urinary bladder cancer	0.000206	0.00042	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—urinary bladder cancer	0.000206	0.00042	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—urinary bladder cancer	0.000205	0.000419	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—urinary bladder cancer	0.000205	0.000418	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000204	0.000417	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000204	0.000416	CcSEcCtD
Aprepitant—Discomfort—Epirubicin—urinary bladder cancer	0.000203	0.000415	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—urinary bladder cancer	0.000202	0.000412	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—urinary bladder cancer	0.000201	0.000411	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—urinary bladder cancer	0.000201	0.00041	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—urinary bladder cancer	0.000201	0.000409	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—urinary bladder cancer	0.000199	0.000406	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—urinary bladder cancer	0.000198	0.000403	CcSEcCtD
Aprepitant—Oedema—Epirubicin—urinary bladder cancer	0.000197	0.000403	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000197	0.000403	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—urinary bladder cancer	0.000197	0.000402	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000197	0.000401	CcSEcCtD
Aprepitant—Infection—Epirubicin—urinary bladder cancer	0.000196	0.0004	CcSEcCtD
Aprepitant—Cough—Doxorubicin—urinary bladder cancer	0.000195	0.000398	CcSEcCtD
Aprepitant—Shock—Epirubicin—urinary bladder cancer	0.000194	0.000396	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—urinary bladder cancer	0.000194	0.000396	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000193	0.000395	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000193	0.000394	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—urinary bladder cancer	0.000193	0.000394	CcSEcCtD
Aprepitant—Tachycardia—Epirubicin—urinary bladder cancer	0.000193	0.000393	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000192	0.000392	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—urinary bladder cancer	0.000192	0.000391	CcSEcCtD
Aprepitant—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000191	0.000389	CcSEcCtD
Aprepitant—Insomnia—Methotrexate—urinary bladder cancer	0.000191	0.000389	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—urinary bladder cancer	0.00019	0.000389	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—urinary bladder cancer	0.00019	0.000389	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—urinary bladder cancer	0.00019	0.000389	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—urinary bladder cancer	0.00019	0.000387	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—urinary bladder cancer	0.000189	0.000386	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000189	0.000386	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—urinary bladder cancer	0.000188	0.000384	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—urinary bladder cancer	0.000188	0.000384	CcSEcCtD
Aprepitant—Dyspnoea—Methotrexate—urinary bladder cancer	0.000188	0.000384	CcSEcCtD
Aprepitant—Somnolence—Methotrexate—urinary bladder cancer	0.000187	0.000383	CcSEcCtD
Aprepitant—Dry mouth—Doxorubicin—urinary bladder cancer	0.000186	0.00038	CcSEcCtD
Aprepitant—Dyspepsia—Methotrexate—urinary bladder cancer	0.000186	0.000379	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—urinary bladder cancer	0.000184	0.000376	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—urinary bladder cancer	0.000184	0.000376	CcSEcCtD
Aprepitant—Decreased appetite—Methotrexate—urinary bladder cancer	0.000183	0.000374	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—urinary bladder cancer	0.000183	0.000373	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000183	0.000373	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000182	0.000371	CcSEcCtD
Aprepitant—Fatigue—Methotrexate—urinary bladder cancer	0.000182	0.000371	CcSEcCtD
Aprepitant—Infection—Doxorubicin—urinary bladder cancer	0.000181	0.00037	CcSEcCtD
Aprepitant—Pain—Methotrexate—urinary bladder cancer	0.00018	0.000368	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00018	0.000367	CcSEcCtD
Aprepitant—Shock—Doxorubicin—urinary bladder cancer	0.00018	0.000367	CcSEcCtD
Aprepitant—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000179	0.000365	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000179	0.000365	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—urinary bladder cancer	0.000178	0.000364	CcSEcCtD
Aprepitant—Tachycardia—Doxorubicin—urinary bladder cancer	0.000178	0.000364	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—urinary bladder cancer	0.000177	0.000362	CcSEcCtD
Aprepitant—Paraesthesia—Epirubicin—urinary bladder cancer	0.000177	0.000362	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000176	0.00036	CcSEcCtD
Aprepitant—Dyspnoea—Epirubicin—urinary bladder cancer	0.000176	0.000359	CcSEcCtD
Aprepitant—Somnolence—Epirubicin—urinary bladder cancer	0.000175	0.000358	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—urinary bladder cancer	0.000174	0.000355	CcSEcCtD
Aprepitant—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000174	0.000355	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—urinary bladder cancer	0.000174	0.000354	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000172	0.000352	CcSEcCtD
Aprepitant—Decreased appetite—Epirubicin—urinary bladder cancer	0.000171	0.00035	CcSEcCtD
Aprepitant—Hypotension—Doxorubicin—urinary bladder cancer	0.000171	0.000348	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00017	0.000348	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—urinary bladder cancer	0.00017	0.000347	CcSEcCtD
Aprepitant—Constipation—Epirubicin—urinary bladder cancer	0.000169	0.000344	CcSEcCtD
Aprepitant—Pain—Epirubicin—urinary bladder cancer	0.000169	0.000344	CcSEcCtD
Aprepitant—Urticaria—Methotrexate—urinary bladder cancer	0.000167	0.000342	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—urinary bladder cancer	0.000167	0.00034	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—urinary bladder cancer	0.000167	0.00034	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000166	0.000339	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—urinary bladder cancer	0.000165	0.000337	CcSEcCtD
Aprepitant—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000164	0.000335	CcSEcCtD
Aprepitant—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000163	0.000332	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000163	0.000332	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—urinary bladder cancer	0.000162	0.000331	CcSEcCtD
Aprepitant—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000161	0.000329	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000161	0.000328	CcSEcCtD
Aprepitant—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000159	0.000324	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000158	0.000322	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—urinary bladder cancer	0.000157	0.000321	CcSEcCtD
Aprepitant—Urticaria—Epirubicin—urinary bladder cancer	0.000157	0.00032	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—urinary bladder cancer	0.000156	0.000319	CcSEcCtD
Aprepitant—Pain—Doxorubicin—urinary bladder cancer	0.000156	0.000319	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—urinary bladder cancer	0.000156	0.000318	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—urinary bladder cancer	0.000156	0.000318	CcSEcCtD
Aprepitant—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000155	0.000317	CcSEcCtD
Aprepitant—Asthenia—Methotrexate—urinary bladder cancer	0.000151	0.000309	CcSEcCtD
Aprepitant—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00015	0.000307	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000149	0.000305	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—urinary bladder cancer	0.000149	0.000304	CcSEcCtD
Aprepitant—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000145	0.000297	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—urinary bladder cancer	0.000145	0.000296	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000144	0.000295	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000144	0.000295	CcSEcCtD
Aprepitant—Diarrhoea—Methotrexate—urinary bladder cancer	0.000144	0.000294	CcSEcCtD
Aprepitant—Asthenia—Epirubicin—urinary bladder cancer	0.000142	0.000289	CcSEcCtD
Aprepitant—Pruritus—Epirubicin—urinary bladder cancer	0.00014	0.000285	CcSEcCtD
Aprepitant—Dizziness—Methotrexate—urinary bladder cancer	0.000139	0.000285	CcSEcCtD
Aprepitant—Diarrhoea—Epirubicin—urinary bladder cancer	0.000135	0.000276	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000134	0.000275	CcSEcCtD
Aprepitant—Vomiting—Methotrexate—urinary bladder cancer	0.000134	0.000274	CcSEcCtD
Aprepitant—Rash—Methotrexate—urinary bladder cancer	0.000133	0.000271	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—urinary bladder cancer	0.000133	0.000271	CcSEcCtD
Aprepitant—Headache—Methotrexate—urinary bladder cancer	0.000132	0.00027	CcSEcCtD
Aprepitant—Asthenia—Doxorubicin—urinary bladder cancer	0.000131	0.000267	CcSEcCtD
Aprepitant—Dizziness—Epirubicin—urinary bladder cancer	0.00013	0.000266	CcSEcCtD
Aprepitant—Pruritus—Doxorubicin—urinary bladder cancer	0.000129	0.000264	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—IGF1—urinary bladder cancer	0.000127	0.000922	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000127	0.000922	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—EGFR—urinary bladder cancer	0.000126	0.000917	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000126	0.000916	CbGpPWpGaD
Aprepitant—Vomiting—Epirubicin—urinary bladder cancer	0.000125	0.000256	CcSEcCtD
Aprepitant—Nausea—Methotrexate—urinary bladder cancer	0.000125	0.000256	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000125	0.000255	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—JAG1—urinary bladder cancer	0.000125	0.00091	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000125	0.000909	CbGpPWpGaD
Aprepitant—Rash—Epirubicin—urinary bladder cancer	0.000124	0.000254	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—urinary bladder cancer	0.000124	0.000254	CcSEcCtD
Aprepitant—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000124	0.000904	CbGpPWpGaD
Aprepitant—Headache—Epirubicin—urinary bladder cancer	0.000124	0.000252	CcSEcCtD
Aprepitant—Dizziness—Doxorubicin—urinary bladder cancer	0.000121	0.000246	CcSEcCtD
Aprepitant—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.00012	0.000877	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—KRAS—urinary bladder cancer	0.000119	0.000867	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	0.000119	0.000865	CbGpPWpGaD
Aprepitant—Nausea—Epirubicin—urinary bladder cancer	0.000117	0.000239	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000117	0.00085	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000116	0.000847	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000116	0.000846	CbGpPWpGaD
Aprepitant—Vomiting—Doxorubicin—urinary bladder cancer	0.000116	0.000237	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—RHOA—urinary bladder cancer	0.000116	0.000845	CbGpPWpGaD
Aprepitant—Rash—Doxorubicin—urinary bladder cancer	0.000115	0.000235	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—urinary bladder cancer	0.000115	0.000235	CcSEcCtD
Aprepitant—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000115	0.000836	CbGpPWpGaD
Aprepitant—Headache—Doxorubicin—urinary bladder cancer	0.000114	0.000233	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000114	0.000831	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000114	0.000831	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	0.000112	0.000817	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.00011	0.000801	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	0.000109	0.000796	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000109	0.000791	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000109	0.000791	CbGpPWpGaD
Aprepitant—Nausea—Doxorubicin—urinary bladder cancer	0.000108	0.000221	CcSEcCtD
Aprepitant—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000108	0.000788	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000108	0.000785	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ERBB2—urinary bladder cancer	0.000107	0.000782	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000107	0.000777	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000106	0.000769	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000104	0.00076	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000104	0.00076	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL8—urinary bladder cancer	0.000102	0.000741	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HRAS—urinary bladder cancer	0.000101	0.000737	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—S100B—urinary bladder cancer	0.000101	0.000737	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	9.94e-05	0.000724	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.8e-05	0.000714	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL2—urinary bladder cancer	9.73e-05	0.000709	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—RHOA—urinary bladder cancer	9.58e-05	0.000698	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	9.54e-05	0.000695	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCND1—urinary bladder cancer	9.48e-05	0.000691	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.27e-05	0.000675	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MMP9—urinary bladder cancer	9.21e-05	0.000671	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CDKN1A—urinary bladder cancer	9.17e-05	0.000668	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	9.16e-05	0.000667	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTEN—urinary bladder cancer	9.15e-05	0.000667	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NCOR1—urinary bladder cancer	9.09e-05	0.000662	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2—urinary bladder cancer	8.85e-05	0.000645	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TYMP—urinary bladder cancer	8.74e-05	0.000637	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EP300—urinary bladder cancer	8.73e-05	0.000636	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	8.59e-05	0.000625	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	8.5e-05	0.000619	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SRC—urinary bladder cancer	8.49e-05	0.000618	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL8—urinary bladder cancer	8.41e-05	0.000613	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.35e-05	0.000608	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.23e-05	0.0006	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	8.11e-05	0.000591	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NAT1—urinary bladder cancer	8.06e-05	0.000587	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	8.06e-05	0.000587	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2—urinary bladder cancer	8.04e-05	0.000586	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TERT—urinary bladder cancer	8.01e-05	0.000584	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.93e-05	0.000578	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NAT2—urinary bladder cancer	7.9e-05	0.000576	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	7.9e-05	0.000576	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	7.75e-05	0.000565	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.67e-05	0.000559	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MYC—urinary bladder cancer	7.61e-05	0.000554	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.56e-05	0.000551	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGFR—urinary bladder cancer	7.44e-05	0.000542	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	7.37e-05	0.000537	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—FGFR3—urinary bladder cancer	7.35e-05	0.000536	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	7.35e-05	0.000535	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NAT1—urinary bladder cancer	7.35e-05	0.000535	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.23e-05	0.000527	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ESR1—urinary bladder cancer	7.14e-05	0.00052	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KRAS—urinary bladder cancer	7.03e-05	0.000512	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—RRM2—urinary bladder cancer	6.82e-05	0.000497	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	6.72e-05	0.00049	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	6.64e-05	0.000484	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	6.62e-05	0.000483	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	6.32e-05	0.00046	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ENO2—urinary bladder cancer	6.32e-05	0.00046	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TYMP—urinary bladder cancer	6.32e-05	0.00046	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	6.28e-05	0.000458	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NAT1—urinary bladder cancer	6.28e-05	0.000458	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	6.27e-05	0.000457	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CREBBP—urinary bladder cancer	6.26e-05	0.000456	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—urinary bladder cancer	6.25e-05	0.000455	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IGF1—urinary bladder cancer	6.18e-05	0.00045	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.18e-05	0.00045	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—EGFR—urinary bladder cancer	6.15e-05	0.000448	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	6.13e-05	0.000446	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	6.11e-05	0.000445	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	6.05e-05	0.000441	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HRAS—urinary bladder cancer	5.97e-05	0.000435	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—KRAS—urinary bladder cancer	5.81e-05	0.000423	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	5.74e-05	0.000418	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	5.72e-05	0.000416	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NAT2—urinary bladder cancer	5.71e-05	0.000416	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RHOA—urinary bladder cancer	5.66e-05	0.000412	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	5.57e-05	0.000406	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ERBB2—urinary bladder cancer	5.24e-05	0.000382	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	5.17e-05	0.000377	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.11e-05	0.000372	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NQO1—urinary bladder cancer	5.09e-05	0.000371	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL8—urinary bladder cancer	4.97e-05	0.000362	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HRAS—urinary bladder cancer	4.94e-05	0.00036	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—RRM2—urinary bladder cancer	4.93e-05	0.000359	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.9e-05	0.000357	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	4.88e-05	0.000356	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.88e-05	0.000356	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.85e-05	0.000353	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.85e-05	0.000353	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	4.76e-05	0.000347	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2—urinary bladder cancer	4.75e-05	0.000346	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.69e-05	0.000342	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCND1—urinary bladder cancer	4.63e-05	0.000337	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.57e-05	0.000333	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.57e-05	0.000333	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MMP9—urinary bladder cancer	4.5e-05	0.000328	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.48e-05	0.000326	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTEN—urinary bladder cancer	4.47e-05	0.000326	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.47e-05	0.000325	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.45e-05	0.000324	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.43e-05	0.000323	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.43e-05	0.000323	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NAT2—urinary bladder cancer	4.42e-05	0.000322	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.28e-05	0.000312	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EP300—urinary bladder cancer	4.26e-05	0.000311	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	4.25e-05	0.000309	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SRC—urinary bladder cancer	4.14e-05	0.000302	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.03e-05	0.000293	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.99e-05	0.000291	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TYMS—urinary bladder cancer	3.95e-05	0.000288	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	3.9e-05	0.000284	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	3.9e-05	0.000284	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.82e-05	0.000278	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.81e-05	0.000278	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TYMP—urinary bladder cancer	3.8e-05	0.000277	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.77e-05	0.000275	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GPX1—urinary bladder cancer	3.74e-05	0.000272	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—urinary bladder cancer	3.71e-05	0.000271	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.68e-05	0.000268	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.67e-05	0.000268	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3.67e-05	0.000267	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.65e-05	0.000266	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—urinary bladder cancer	3.63e-05	0.000265	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.53e-05	0.000257	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.53e-05	0.000257	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.51e-05	0.000256	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.48e-05	0.000253	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	3.45e-05	0.000251	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.44e-05	0.000251	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—urinary bladder cancer	3.43e-05	0.00025	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.42e-05	0.000249	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.37e-05	0.000246	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.22e-05	0.000235	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.22e-05	0.000235	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.2e-05	0.000233	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.12e-05	0.000227	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.07e-05	0.000224	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	3.07e-05	0.000224	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—urinary bladder cancer	3.05e-05	0.000222	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.97e-05	0.000216	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.94e-05	0.000214	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—urinary bladder cancer	2.92e-05	0.000213	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.85e-05	0.000208	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.85e-05	0.000207	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.82e-05	0.000206	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.82e-05	0.000206	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.8e-05	0.000204	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.76e-05	0.000201	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.75e-05	0.0002	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.75e-05	0.0002	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.73e-05	0.000199	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.7e-05	0.000197	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.69e-05	0.000196	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.67e-05	0.000194	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.66e-05	0.000193	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.65e-05	0.000193	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.63e-05	0.000191	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.59e-05	0.000189	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.52e-05	0.000183	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.49e-05	0.000182	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.41e-05	0.000175	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.37e-05	0.000173	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.3e-05	0.000167	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.29e-05	0.000167	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.22e-05	0.000162	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.21e-05	0.000161	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	2.2e-05	0.00016	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.2e-05	0.00016	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.18e-05	0.000159	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.18e-05	0.000159	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.16e-05	0.000158	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.15e-05	0.000157	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.12e-05	0.000155	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.12e-05	0.000155	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.09e-05	0.000153	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.09e-05	0.000152	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.06e-05	0.00015	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.05e-05	0.000149	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.02e-05	0.000147	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.01e-05	0.000147	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.99e-05	0.000145	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.99e-05	0.000145	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.94e-05	0.000142	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.93e-05	0.00014	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.92e-05	0.00014	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.9e-05	0.000139	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.88e-05	0.000137	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.87e-05	0.000136	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.85e-05	0.000135	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.83e-05	0.000133	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.79e-05	0.00013	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.76e-05	0.000128	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.72e-05	0.000125	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.71e-05	0.000125	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.7e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.7e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.63e-05	0.000119	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.6e-05	0.000116	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.59e-05	0.000116	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.56e-05	0.000114	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.5e-05	0.000109	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.5e-05	0.000109	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.43e-05	0.000104	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.43e-05	0.000104	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.39e-05	0.000101	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.37e-05	9.97e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.33e-05	9.67e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.32e-05	9.64e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	9.56e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	9.56e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.26e-05	9.15e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	8.98e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.23e-05	8.96e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.22e-05	8.87e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.17e-05	8.52e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.16e-05	8.44e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.12e-05	8.17e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.07e-05	7.81e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.02e-05	7.45e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTEN—urinary bladder cancer	9.78e-06	7.12e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	9.58e-06	6.98e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.4e-06	6.85e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—EP300—urinary bladder cancer	9.32e-06	6.79e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.03e-06	6.58e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.36e-06	6.09e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—EP300—urinary bladder cancer	7.97e-06	5.81e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.39e-06	5.39e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.45e-06	4.7e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.15e-06	4.48e-05	CbGpPWpGaD
